Neostriatal glutamatergic system is involved in the pathogenesis of picrotoxin-induced choreomyoclonic hyperkinesis

Bulletin of Experimental Biology and Medicine

Volumn 138, Issue 6, 2004, Pages 533-536

  Yakimovskii, A F ^a,b   Varshavskaya, V M ^a,b  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

Author keywords

GABA; Glutamate; Hyperkinesias; MK 801; Neostriatum; Picrotoxin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE; GLUTAMIC ACID; PICROTOXIN;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; COGNITIVE DEFECT; CONDITIONED REFLEX; CONTROLLED STUDY; CONVULSION; DISEASE ASSOCIATION; DRUG POTENTIATION; EXPLORATORY BEHAVIOR; EXTRAPYRAMIDAL SYNDROME; GABAERGIC SYSTEM; HUNTINGTON CHOREA; HYPERKINESIA; LOCOMOTION; MALE; MICROINJECTION; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NEOSTRIATUM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RAT; RAT STRAIN; REPRODUCIBILITY; STUDENT T TEST;

ANIMALS; CORPUS STRIATUM; GLUTAMIC ACID; MALE; MICROINJECTIONS; PICROTOXIN; RATS; RATS, WISTAR; RECEPTORS, GABA-A; REPRODUCIBILITY OF RESULTS;

EID: 17144397671     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-005-0119-3     Document Type: Article

References (14)

1. V. M. Varshavskaya, O. N. Ivanova, and A. F. Yakimovskii, Ros. Fiziol. Zh., 88, No.10, 1317-1323 (2002).
2. S. N. Illarioshkin, Conformational Diseases of the Brain [in Russian], Moscow (2003), p. 248.
3. A. F. Yakimovskii, Byull. Eksp. Biol. Med., 114, No.1, 7-9 (1993).
4. T. Arzberger, K. Krampfl, S. Leimgruber, and A. Weindl, J. Neuropathol. Exp. Neurol., 56, No.4, 440-454 (1997).
5. B. G. Jenkins, H. D. Rosas, Y. C. Chen, et al., Neurology, 50, No.5, 1357-1365 (1998). 1:STN:280:DyaK1c3lsFChtA%3D%3D
6. M. Lesort, W. Chun, J. Tucholski, and G. V. Johnson, Neurochem. Intern., 40, No.1, 37-52 (2002).
7. L. V. Metman, M. J. Morris, C. Farmer, et al., Neurology, 59, No.5, 694-699 (2002).
8. T. L. Perry and S. Hansen, Ibid., 40, No.1, 20-24 (1990).
9. H. D. Rosas, W. J. Koroshetz, Y. I. Chen, et al., Ibid., 60, No.10, 1615-1620 (2003).
10. Ch. A. Ross and R. L. Margolis, Neuropsychopharmacology: The Fifth Generation of Progress, Eds. K. L. Davis et al., New York (2002), pp. 1817-1830.
11. R. Sattler, Z. Xiong, W. Y. Lu, et al., J. Neurosci., 20, No.1, 22-23 (2000).
12. J. C. Villares and J. C. Stavale, Exp. Neurol., 172, No.2, 391-404 (2002).
13. J. P. Vonsattel, R. H. Myers, T. J. Stevens, et al., J. Neuropathol. Exp. Neurol., 44, No.6, 559-577 (1985).
14. M. V. Wagster, J. C. Hedreen, C. E. Peyser, et al., Exp. Neurol., 127, No.1, 70-75 (1994).